Research-use notice: This article is educational and summarises preclinical and experimental research on TB-500 (thymosin beta-4 fragment). It is not medical advice. Nootropix peptides are labeled RUO (Research Use Only) and are not for human or veterinary use.
Quick take
- What it is: TB-500 is a synthetic peptide corresponding to the active region of thymosin beta-4 (Tβ4) — a 43-amino-acid protein abundant in platelets, wound fluid, and many tissues.
- Evidence tier: Strongest data attach to the full thymosin beta-4 molecule in cardiac, neuro, and dermal models. TB-500-specific human injury data are limited; much online discussion extrapolates from parent-protein literature.
- Why researchers study it: Actin regulation, cell migration, angiogenesis, and extracellular matrix remodelling in wound and tissue-repair models.
- Routes in literature: Subcutaneous, intraperitoneal, and local administration appear in different model types — route choice changes interpretation.
- Nootropix stocks: COA-verified TB-500 lyophilized vials in 2 mg, 5 mg, and 10 mg sizes.
- Cluster hub: Use the guides below for BPC-157 comparison, tissue models, dosing context, and product verification.
| Guide | Best for | Link |
|---|---|---|
| This hub | TB-500 mechanisms, evidence map, safety, COA | TB-500 Research Overview |
| BPC-157 hub | Complementary repair peptide — tissue, gut, dosing | BPC-157 Research Overview |
| vs TB-500 | Side-by-side comparison for injury recovery goals | BPC-157 vs TB-500 |
| Tissue & injury recovery | Tendon, ligament, muscle models (BPC-157 focus) | Tissue Healing Guide |
| Product | COA-verified vials, variants, reconstitution | TB-500 PDP |
| Peptides pillar | Catalog and reconstitution calculator | Peptides |
View TB-500 COA-Verified Vials
Contents
- What is TB-500?
- Proposed mechanisms (preclinical)
- Evidence map by research domain
- Dosing and protocol variables
- Safety and regulatory context
- COA and batch verification
- FAQ
What Is TB-500?
TB-500 is the common name for a synthetic peptide fragment derived from thymosin beta-4 (Tβ4) — a naturally occurring 43-amino-acid protein involved in actin dynamics, cell motility, and tissue repair signalling. The fragment sold as TB-500 typically corresponds to the active region around amino acids 17–23 (LKKTETQ), though vendor nomenclature varies.
Important distinction: thymosin beta-4 (full protein) and TB-500 (fragment) are not identical molecules. Most positive medical literature references the full Tβ4 protein in controlled trials and specialised models. TB-500 is cheaper to synthesise and is the form most commonly sold for research, but evidence should not be assumed to transfer one-to-one.
TB-500 is not an approved pharmaceutical in major jurisdictions. Online discussion frequently outpaces the evidence base. This guide maps what preclinical studies actually measure — and what they do not prove in humans.
Nootropix supplies TB-500 as lyophilized research material in 2 mg, 5 mg, and 10 mg vials. Batch documentation is available through our COA Library.
What TB-500 is not:
- Not a proven human therapy for tendons, wounds, or any clinical condition
- Not WADA-permitted — thymosin beta-4 and its derivatives are prohibited for tested athletes
- Not interchangeable with full thymosin beta-4 without independent evidence for your endpoint
- Not interchangeable across vendors without batch COA review — sequence identity and endotoxin matter for any lab work
Proposed Mechanisms (Preclinical)
Mechanism descriptions are hypothesis-generating. No single pathway is confirmed as the definitive explanation for all reported model outcomes. Researchers typically discuss several overlapping signals:
| Pathway | What preclinical literature discusses | Hedged framing |
|---|---|---|
| Actin regulation | Sequestration of G-actin; promotion of cell migration via actin polymerisation | May help repair cells reach injury sites; model-dependent |
| Cell migration | Fibroblast, keratinocyte, and endothelial cell motility in wound models | May support granulation tissue formation; not mapped in humans |
| Angiogenesis | New vessel formation discussed in cardiac and dermal injury models (often Tβ4 parent) | May improve perfusion at injury sites; theoretical tumour-feeding concern unproven |
| Collagen remodelling | Matrix deposition and scar minimisation endpoints in wound closure models | May influence tissue structure; magnitude varies by model |
| Anti-inflammatory signals | Reduction of inflammatory mediators in some tissue injury setups | Highly model-specific; cautious interpretation required |
These pathways are discussed across rodent wound models, cardiac injury models, and dermal healing setups. Results should not be pooled as if they were one uniform "effect size."
Evidence Map by Research Domain
Use this section as a routing table. Where BPC-157 has dedicated satellite guides, TB-500 evidence is consolidated here with comparison links to the vs post.
Musculoskeletal and soft tissue
Animal models explore whether thymosin beta-4 family peptides influence tendon, ligament, and muscle recovery through cell migration and matrix remodelling rather than the angiogenic/NO framing often applied to BPC-157. Endpoints include histology, collagen organisation, and functional recovery time.
Direct TB-500-specific musculoskeletal RCT data in humans are scarce. Much comparison discussion routes through the BPC-157 vs TB-500 framework.
Go deeper: BPC-157 vs TB-500 for Healing · BPC-157 Tissue Healing Guide
Cardiac and neurological (parent molecule)
Full thymosin beta-4 has been studied in rodent models of myocardial infarction, stroke, and traumatic brain injury. Reported endpoints include reduced infarct size, improved ejection fraction, and neurobehavioural recovery in specialised setups.
These data primarily attach to the full Tβ4 protein, not necessarily the TB-500 fragment sold online. Treat cardiac and neuro claims as parent-molecule literature unless a study explicitly used the fragment sequence.
Dermal and wound healing
Dermal wound models evaluate closure rate, re-epithelialisation, and angiogenesis at the wound bed. Thymosin beta-4 appears in corneal and skin wound literature. Phase I/II trials of Tβ4 formulations for venous stasis ulcers and pressure sores have been reported for the parent molecule — not for TB-500 specifically.
Go deeper: BPC-157 vs TB-500 for goal-based comparison (tendon vs structure vs gut).
Stacking context: BPC-157 + TB-500
Some preclinical discussions explore complementary mechanisms — BPC-157 often framed around local repair signalling and angiogenesis; TB-500 around cell migration and actin regulation. Combination protocols are common in online discourse but lack robust human RCT validation.
Go deeper: BPC-157 Research Overview · BPC-157 vs TB-500
Dosing and Protocol Variables
There are no approved clinical dosing guidelines for TB-500. Preclinical papers use widely different species, routes (SC, IP, local), and dose ranges. Online "loading and maintenance" schedules are anecdotal extrapolations, not regulatory standards.
Researchers typically document:
- Species and model — rat vs mouse, acute wound vs chronic injury
- Route — systemic vs local changes pharmacokinetics and interpretation
- Frequency and duration — single bolus vs multi-week schedules
- Fragment vs full protein — dose equivalence is not established
- Endpoints — histology, biomechanics, functional tests, biomarkers
Nootropix stocks 2 mg, 5 mg, and 10 mg vials. Any institution working with TB-500 should design protocols from primary literature and institutional SOPs — not from forum copy-paste.
Reconstitution: Standard peptide handling applies. See Peptides Guide & Reconstitution Calculator.
Safety and Regulatory Context
Phase I trials of full thymosin beta-4 reported tolerability at tested doses in some indications, but systematic long-term toxicology for TB-500 specifically is not established. Major regulators have not approved TB-500 as a medicine.
WADA / anti-doping: Thymosin beta-4 and its derivatives (including TB-500) are prohibited for tested athletes under growth-factor and related categories. Anti-doping literature frequently discusses detection methods for TB-500 in equine and human sport. If you are subject to drug testing, do not use these compounds without explicit medical and regulatory clearance.
Preclinical safety summaries often note:
- Limited acute toxicity signals at tested doses in animal models (mostly parent molecule)
- Insufficient long-term human safety data for the fragment
- Theoretical angiogenesis/tumour concerns — not proven, but caution in oncology contexts
- Quality risk from unverified vendors (endotoxins, mislabeled sequences) — see COA section
Any institution working with TB-500 should perform its own risk assessment, follow local regulations, and consult ethics and biosafety boards. This guide does not endorse human self-administration or therapeutic use.
COA and Batch Verification
For research materials, identity and purity documentation matter as much as the compound name on the label. Before any lab work, verify:
- Peptide identity — thymosin beta-4 fragment sequence confirmation where reported
- Purity — HPLC or equivalent analytical method per batch
- Endotoxin — especially for any injectable model (research context)
- Residual solvents — manufacturing compliance
- Batch number — matches the vial you received
Review batch-specific certificates in the COA Library and on the TB-500 product page. Do not accept marketing purity claims without a matching COA for your lot.
Shop TB-500 COA-Verified Vials
FAQ
What is the difference between TB-500 and thymosin beta-4?
Thymosin beta-4 is the full 43-amino-acid protein. TB-500 is a synthetic fragment containing the active healing sequence (commonly amino acids 17–23). Most positive medical trial data references the full protein; TB-500 is the research form most commonly sold online.
Is there human clinical trial evidence for TB-500?
Robust, injury-specific human RCT data for the TB-500 fragment are limited. Some human data exist for full thymosin beta-4 in wound and cardiac contexts. Do not assume fragment equivalence.
Should TB-500 be stacked with BPC-157 in research?
Some preclinical discussions explore complementary mechanisms, but combination protocols are not standardised and lack human validation. See BPC-157 vs TB-500 and the BPC-157 hub for comparison frameworks.
Is TB-500 banned in sport?
Yes. WADA and major anti-doping bodies prohibit thymosin beta-4 and its derivatives. Using TB-500 can result in a doping violation for tested athletes.
What vial sizes does Nootropix stock?
2 mg, 5 mg, and 10 mg lyophilized TB-500 vials with published COAs.
How do I reconstitute peptide vials for lab use?
Standard peptide handling applies: bacteriostatic water, sterile technique, cold storage. See Peptides Guide & Reconstitution Calculator.
